Blood bank for studying atrial fibrillation and stroke genes
Collects blood from people with atrial fibrillation or stroke to study genetic causes.
Plain-language title generated from the registry record
Registry title: Biological Bank for Atrial Fibrillation and Stroke
Key facts
- Where
- Bourg-en-Bresse, Bron, Pierre-Bénite, and Villeurbanne, FranceSee the 5 sites
Where in France
- Service neurologie Centre hospitalier FleyriatBourg-en-Bresse, FranceTaking people
- Service d'urgences Neurovasculaires - service de neurologie vasculaire , Hôpital Pierre WertheimerBron, FranceTaking people
- Service de rythmologie, hôpital cardiologique Louis PradelBron, FranceTaking people
- Service de médecine gériatrique Centre hospitalier Lyon Sud, Groupement hospitalier SudPierre-Bénite, FranceTaking people
- Hôpital des CharpennesVilleurbanne, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hospices Civils de Lyon
- Trial code
- NCT03611816
- Record updated
- 17 April 2026
- Original description
Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in clinical practice. This arrhythmia is responsible for 15% of strokes and more than 30% of strokes on people over 65 years.Read full original descriptionShow less
Biological Bank for Studies Related to Atrial Fibrillation and Stroke
Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in clinical practice. This arrhythmia is responsible for 15% of strokes and more than 30% of strokes on people over 65 years.
According to studies, 30 to 40% of isolated atrial fibrillations could be familial. Atrial fibrillation has significant genetic heterogeneity. About 40 genes have been identified as potentially involved. Studies have identified genes common to the risk of atrial fibrillation and stroke. Despite the pathophysiology of atrial fibrillation has been intensively and extensively studied for almost a century, there are still many questions. The pathophysiology is not sufficiently understood to allow finding more effective therapies. It is necessary to identify genetic determinants and thus potentially new pharmacological targets more adapted.
The establishment of a biological database will test hypotheses concerning the genetic origin and thromboembolic process of atrial fibrillation and associated stroke.
Group 1a; Inclusion Criteria :; AF history; Exclusion Criteria :; No AF history; patient who didn't signed consent; Group 1b; Inclusion Criteria :; AF history; Scheduled electrophysiological exploration or AF ablation; Exclusion Criteria :; No AF history; pregnant women; patient who didn't signed consent; Group 1c; Inclusion Criteria :; AF/AT history; Stroke history; Exclusion Criteria :; No Stroke history; patient who didn't signed consent; Group 2; Inclusion Criteria :; patient over 80; ECG: sinusal rhythm; TTE : no left atrial dilatation; Exclusion Criteria :; atrial fibrillation history; TTE : Left atria >25cm², > 34m/m2), FEVG < 50%; ECG : QRS > 90 ms; cardiac pathologies (excepted hypertension and valvulopathies); History of stroke and transient ischemic attack; patient who didn't signed consent; Group 3; Inclusion Criteria :; cryptogenic stroke or transient ischemic attack history before 50 yo; No AF history; Exclusion Criteria :; AF history; stroke or transient ischemic attack over 50 yo; patient who didn't signed consent.